ALK vs. PXS, CLCO, ICON, PAA, GEL, MMP, AAL, CCL, SAVE, and GNK
Should you be buying Alkemy Capital Investments stock or one of its competitors? The main competitors of Alkemy Capital Investments include Provexis (PXS), CloudCoCo Group (CLCO), Iconic Labs (ICON), 22532 (PAA.L) (PAA), Greka Engineering & Technology (GEL), Marwyn Management Partners (MMP), Anglo American (AAL), Carnival Co. & (CCL), Savannah Energy (SAVE), and Greene King (GNK). These companies are all part of the "transportation" industry.
Alkemy Capital Investments vs.
Provexis (LON:PXS) and Alkemy Capital Investments (LON:ALK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.
Alkemy Capital Investments received 92 more outperform votes than Provexis when rated by MarketBeat users. Likewise, 76.88% of users gave Alkemy Capital Investments an outperform vote while only 64.21% of users gave Provexis an outperform vote.
In the previous week, Provexis' average media sentiment score of 0.00 equaled Alkemy Capital Investments'average media sentiment score.
7.9% of Provexis shares are owned by institutional investors. Comparatively, 1.5% of Alkemy Capital Investments shares are owned by institutional investors. 21.6% of Provexis shares are owned by insiders. Comparatively, 43.7% of Alkemy Capital Investments shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Provexis has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Alkemy Capital Investments has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500.
Alkemy Capital Investments has a net margin of 0.00% compared to Provexis' net margin of -73.10%. Alkemy Capital Investments' return on equity of 181.08% beat Provexis' return on equity.
Provexis has higher revenue and earnings than Alkemy Capital Investments. Provexis is trading at a lower price-to-earnings ratio than Alkemy Capital Investments, indicating that it is currently the more affordable of the two stocks.
Summary
Alkemy Capital Investments beats Provexis on 7 of the 12 factors compared between the two stocks.
Get Alkemy Capital Investments News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALK and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkemy Capital Investments Competitors List
Related Companies and Tools
This page (LON:ALK) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy ALK Stock Free ALK Stock Alerts